Eli Lilly is losing share in India’s GLP-1 market as low-cost semaglutide generics accelerate, while Novo Nordisk is holding steady after making deep price cuts to defend Ozempic and Wegovy. The article points to pricing pressure and intensifying competition in a key emerging market rather than a broader industry shock. Net impact is mildly negative for Lilly, with Novo’s aggressive defense limiting further share loss.
Eli Lilly is losing share in India’s GLP-1 market as low-cost semaglutide generics accelerate, while Novo Nordisk is holding steady after making deep price cuts to defend Ozempic and Wegovy. The article points to pricing pressure and intensifying competition in a key emerging market rather than a broader industry shock. Net impact is mildly negative for Lilly, with Novo’s aggressive defense limiting further share loss.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.35
